RHYTHM PHARMACEUTICALS INC. - COMMON STOCK

59,94

22-ноября-24 16:44:58

15 мин. задержка

Акции

+0,91

+1,54%

Сегодняшний диапазон

59,00 - 60,25

ISIN

N/A

Источник

NASDAQ

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

18 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology

13 ноя 2024 18:30:00 Источник Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants

13 ноя 2024 16:01:00 Источник Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

06 ноя 2024 08:00:00 Источник Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update

05 ноя 2024 16:01:00 Источник Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024

04 ноя 2024 16:01:00 Источник Nasdaq GlobeNewswire
Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome

24 окт 2024 06:00:00 Источник Nasdaq GlobeNewswire
Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024

23 окт 2024 08:00:01 Источник Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants

08 окт 2024 16:01:00 Источник Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants

16 сен 2024 16:01:00 Источник Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old

26 авг 2024 08:02:00 Источник Nasdaq GlobeNewswire
Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September

26 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants

13 авг 2024 16:01:00 Источник Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update

06 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

31 июл 2024 09:10:21 Источник Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity

23 июл 2024 08:00:00 Источник Nasdaq GlobeNewswire
Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

23 июл 2024 07:30:00 Источник Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants

11 июл 2024 16:01:00 Источник Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer

08 июл 2024 08:00:00 Источник Nasdaq GlobeNewswire
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency

28 июн 2024 08:00:14 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.